Log in
NASDAQ:ZIOP

ZIOPHARM Oncology Stock Forecast, Price & News

$2.09
-0.10 (-4.57 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.06
Now: $2.09
$2.19
50-Day Range
$2.19
MA: $2.57
$2.95
52-Week Range
$1.79
Now: $2.09
$5.61
Volume2.47 million shs
Average Volume1.93 million shs
Market Capitalization$447.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Read More
ZIOPHARM Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970
Employees73

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$0.52 per share

Profitability

Net Income$-117,800,000.00

Miscellaneous

Market Cap$447.58 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$2.09
-0.10 (-4.57 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

How has ZIOPHARM Oncology's stock been impacted by Coronavirus?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZIOP stock has decreased by 17.7% and is now trading at $2.09.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ZIOPHARM Oncology?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ZIOPHARM Oncology
.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for ZIOPHARM Oncology
.

How can I listen to ZIOPHARM Oncology's earnings call?

ZIOPHARM Oncology will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). During the same quarter in the previous year, the business posted ($0.09) EPS.
View ZIOPHARM Oncology's earnings history
.

What price target have analysts set for ZIOP?

5 Wall Street analysts have issued 12 month price targets for ZIOPHARM Oncology's shares. Their forecasts range from $5.50 to $7.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $6.30 in the next year. This suggests a possible upside of 201.4% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology
.

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), Opko Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Dr. Laurence James Neil Cooper, CEO & Director (Age 55, Pay $1.7M)
  • Mr. Satyavrat Shukla C.F.A., Exec. VP & CFO (Age 48, Pay $451.2k)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 64, Pay $402.57k)
  • Mr. Robert Hadfield, Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 42, Pay $517.72k)
  • Dr. David M. Mauney M.D., Consultant (Age 51, Pay $686.01k)
  • Ms. Lynn M. Ferrucci, Exec. VP of HR, Facilities, Admin. & IT
  • Christopher Taylor, VP of Investor Relations & Corp. Communications
  • Ms. Jill Buck, Exec. VP & GM of Gene Therapy (Age 46)
  • Dr. Eleanor De Groot, Exec. VP & GM of Cell Therapy (Age 51)
  • Dr. Drew Deniger, Head of TCR-T Cell Therapy Program

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include BNP Paribas Arbitrage SA (0.02%), Allred Capital Management LLC (0.01%), David Loasby (0.01%), Cambridge Investment Research Advisors Inc. (0.01%) and XTX Markets LLC (0.01%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology
.

Which institutional investors are buying ZIOPHARM Oncology stock?

ZIOP stock was bought by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, David Loasby, Cambridge Investment Research Advisors Inc., XTX Markets LLC, and Allred Capital Management LLC.
View insider buying and selling activity for ZIOPHARM Oncology
.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $2.09.

How big of a company is ZIOPHARM Oncology?

ZIOPHARM Oncology has a market capitalization of $447.58 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-117,800,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. ZIOPHARM Oncology employs 73 workers across the globe.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is www.ziopharm.com.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.